NIPD GENETICS PUBLIC COMPANY LTD has a total of 27 patent applications. It increased the IP activity by 1700.0%. Its first patent ever was published in 2016. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets biotechnology and computer technology are PATHOGENICA INC, SIGNATURE DIAGNOSTICS AG and ZORAGEN BIOTECHNOLOGIES LLP.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 5 | |
#4 | Canada | 5 | |
#5 | Hong Kong | 1 | |
#6 | United States | 1 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Computer technology |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Bioinformatics | |
#3 | Microorganisms | |
#4 | Electric digital data processing |
# | Name | Total Patents |
---|---|---|
#1 | Koumbaris George | 26 |
#2 | Kypri Elena | 22 |
#3 | Tsangaras Kyriakos | 20 |
#4 | Patsalis Philippos | 20 |
#5 | Ioannides Marios | 19 |
#6 | Mina Petros | 18 |
#7 | Achilleos Acilleas | 14 |
#8 | Loizides Charalambos | 10 |
#9 | Achilleos Achilleas | 7 |
#10 | Papageorgiou Elisavet A | 5 |
Publication | Filing date | Title |
---|---|---|
EP3696279A1 | Methods for noninvasive prenatal testing of fetal abnormalities | |
EP3696278A1 | Method of determining the origin of nucleic acids in a mixed sample | |
WO2019008167A1 | Target-enriched multiplexed parallel analysis for assessment of risk for genetic conditions | |
EP3649260A1 | Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers | |
AU2018296568A1 | Enrichment of targeted genomic regions for multiplexed parallel analysis | |
WO2019008153A1 | Target-enriched multiplexed parallel analysis for assessment of fetal dna samples | |
AU2016269332A1 | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |